Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study

BACKGROUND/AIM: Sorafenib is the first systemic therapy for the treatment of advanced-stage hepatocellular carcinoma (HCC) and progressive HCC after locoregional therapy. The aim of this study was to evaluate the prognostic factors of long-term survivors after sorafenib treatment. METHODS: This mult...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Young Youn, Yu, Su Jong, Lee, Hye Won, Kim, Do Young, Kang, Wonseok, Paik, Yong-Han, Sung, Pil Soo, Bae, Si Hyun, Park, Su Cheol, Doh, Young Seok, Kim, Kang Mo, Jang, Eun Sun, Kim, In Hee, Kim, Won, Kim, Yoon Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219232/
https://www.ncbi.nlm.nih.gov/pubmed/34169044
http://dx.doi.org/10.2147/JHC.S304439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219232/
https://www.ncbi.nlm.nih.gov/pubmed/34169044
http://dx.doi.org/10.2147/JHC.S304439

Ejemplares similares